Article

FGFR2 promotes resistance to ALK tyrosine kinase inhibitors and its inhibition acts synergistically with lorlatinib in the treatment of ALK-expressing neuroblastoma

2024-09-10

Abstract excerpt

<h4>ABSTRACT</h4> Anaplastic Lymphoma Kinase inhibitors (ALK TKIs) are approved for the treatment of ALK-positive non-small cell lung cancer (NSCLC) and are in clinical trial for ALK-aberrant high-risk neuroblastoma (NB) patients, particularly loratinib. However, resistance to ALK inhibitors can occur in patients, via the activation of bypass-signalling pathways, and there is a need to identify these mechanisms a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 562d32e4-df89-55b5-a474-ad0a24c0c0a2
DOI: 10.1101/2024.09.05.611416

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

FGFR2 promotes resistance to ALK tyrosine kinase inhibitors and its inhibition acts synergistically with lorlatinib in the treatment of ALK-expressing neuroblastomaDOI 10.1101/2024.09.05.611416Read

RAS-MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK Blockade.Semantic proximity Read

FGFR blockade inhibits targeted therapy-tolerant persister cells in basal FGFR1 and FGF2 high expressing cancers with driver oncogenesSemantic proximity Read

Functional identification of molecular oncotargets associated with the resistance to ALK inhibition in neuroblastoma via genome-wide CRISPR-Cas9 screensSemantic proximity Read

Dissecting signaling regulators driving AXL-mediated bypass resistance and associated phenotypes by phosphosite perturbationsSemantic proximity Read

Targeting the Fibroblast Growth Factor Receptor (FGFR) Family in Lung Cancer.Semantic proximity Read

FGFR1 is a Potential Therapeutic Target in NeuroblastomaSemantic proximity Read

FGFR-driven lung cancer: Dissecting resistance and exploring therapeutic avenues.Semantic proximity Read

Rapidly Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in NSCLC Cell Lines through De-Repression of FGFR2 and FGFR3 ExpressionSemantic proximity Read

FGFR-TKI resistance in cancer: current status and perspectives.Semantic proximity Read

Efficacy of RMC-6236 (Daraxonrasib) and novel combination strategies targeting resistance in RAS pathway-driven neuroblastomaSemantic proximity Read

Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapySemantic proximity Read

Rationale for targeting fibroblast growth factor receptor signaling in breast cancer.Semantic proximity Read